ID   Hermes 1
AC   CVCL_VS06
SY   Hermes1; Human extended-replication melanocytes-1
DR   GEO; GSM555117
DR   GEO; GSM555169
DR   Wikidata; Q94104090
RX   PubMed=12759390;
RX   PubMed=21343389;
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Ala76Cysfs*64 (c.225_243del19) (p.Arg90Valfs*76, c.268_286del19) (p16-Leiden); ClinVar=VCV000182411; Zygosity=Homozygous (PubMed=12759390).
CC   Genetic integration: Method=Transduction; Gene=HGNC; HGNC:11730; TERT.
CC   Genetic integration: Method=Transduction; Gene=UniProtKB; P13249; S.alboniger pac (PuroR).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
CC   Cell type: Melanocyte of skin; CL=CL_1000458.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_VS14 ! Hmel-p16-1
SX   Male
AG   24Y
CA   Telomerase immortalized cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 10
//
RX   PubMed=12759390; DOI=10.1093/jnci/95.10.723;
RA   Sviderskaya E.V., Gray-Schopfer V.C., Hill S.P., Smit N.P.,
RA   Evans-Whipp T.J., Bond J., Hill L., Bataille V., Peters G.,
RA   Kipling D., Wynford-Thomas D., Bennett D.C.;
RT   "p16/cyclin-dependent kinase inhibitor 2A deficiency in human
RT   melanocyte senescence, apoptosis, and immortalization: possible
RT   implications for melanoma progression.";
RL   J. Natl. Cancer Inst. 95:723-732(2003).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958; PMCID=PMC3070783;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//